Meridian BioSciences
Needs attentionClinical-stage biotech developing an oral therapy for chronic inflammatory disease, currently in Phase II.
BiotechSeries CSwitzerlandInvested Dec 3, 2019Lead: Jerry
Next board meeting
Tue, August 25
in 4 weeks
Status rationale: A competing therapy received fast-track designation, and the Phase II timeline slipped a quarter on recruitment.Updated Jul 27, 2026
ARR
£0.0m
Budget: £0.0m0%
ARR Growth
0.0%
Budget: 0.0%0%
Cash Balance
£38.4m
Budget: £41.0m-6%
Cash below plan
Net Burn
£2.9m
Budget: £2.6m+12%
Burn above plan
Runway
13.2 mo
Budget: 15.8 mo-16%
Runway behind plan
Gross Margin
0.0%
Budget: 0.0%0%
Net Revenue Retention
0.0%
Budget: 0.0%0%
Churn
0.0%
Budget: 0.0%0%
Pipeline Value
£0.0m
Budget: £0.0m0%
ARR Trend (last 5 quarters)
- £0.0mQ2 25
- £0.0mQ3 25
- £0.0mQ4 25
- £0.0mQ1 26
- £0.0mQ2 26
Metrics
Actuals vs plan, with extraction confidence.
| Metric | Value | vs. plan | Confidence |
|---|---|---|---|
| ARR | £0.0m | On plan | 60% |
| ARR Growth | 0.0% | On plan | 60% |
| Cash Balance | £38.4m | Off plan | 95% |
| Net Burn | £2.9m | Off plan | 84% |
| Runway | 13.2 mo | Off plan | 70% |
| Gross Margin | 0.0% | On plan | 30% |
| Net Revenue Retention | 0.0% | On plan | 30% |
| Churn | 0.0% | On plan | 30% |
| Pipeline Value | £0.0m | On plan | 30% |